Abstract: Provided herein are 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)thiophene-2-carboxamide derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Provided herein are 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)thiophene-2-carboxamide derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the treatment or prophylaxis of dry eye syndrome and in particular dry eye, ocular neuropathic pain, ocular trauma and post-operative ocular pain.

Abstract: A method may include obtaining a topology of an optical network. The topology may indicate multiple optical links within the optical network. The method may also include determining a signal noise tolerance for each of multiple optical signal types supported by the optical network and obtaining an optical noise for each of the multiple optical links. The method may also include determining a number of the multiple optical signal types that each of the multiple optical links is able to support based on the optical noise for each of the optical links and the signal noise tolerance for each of the multiple optical signal types and ranking the multiple optical links based on the number of the multiple optical signal types that each of the optical links is able to support.

Abstract: Provided herein are 2-amino-pyrazolyl-[1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: A method may include obtaining a topology of an optical network. The topology may indicate multiple optical links within the optical network. The method may also include obtaining a routing metric for each of the optical links. The routing metric may be used in selecting routes through the optical network along the multiple optical links. The method may further include obtaining a signal noise tolerance of an optical signal to be routed through the optical network and adjusting routing metrics of one or more of the multiple optical links based on the signal noise tolerance of the optical signal. The method may also include after the routing metrics of the one or more of the multiple optical links are adjusted, determining a route for the optical signal through the optical network along two or more of the multiple optical links based on the routing metrics of the multiple optical links.

Abstract: A method may include obtaining a topology of an optical network. The topology may indicate multiple optical links within the optical network. The method may also include determining a signal noise tolerance for each of multiple optical signal types supported by the optical network and obtaining an optical noise for each of the multiple optical links. The method may also include determining a number of the multiple optical signal types that each of the multiple optical links is able to support based on the optical noise for each of the optical links and the signal noise tolerance for each of the multiple optical signal types and ranking the multiple optical links based on the number of the multiple optical signal types that each of the optical links is able to support.

Abstract: A method may include obtaining a topology of an optical network. The topology may indicate multiple optical links within the optical network. The method may also include obtaining a routing metric for each of the optical links. The routing metric may be used in selecting routes through the optical network along the multiple optical links. The method may further include obtaining a signal noise tolerance of an optical signal to be routed through the optical network and adjusting routing metrics of one or more of the multiple optical links based on the signal noise tolerance of the optical signal. The method may also include after the routing metrics of the one or more of the multiple optical links are adjusted, determining a route for the optical signal through the optical network along two or more of the multiple optical links based on the routing metrics of the multiple optical links.

Abstract: Compositions, devices, method of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides and electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least on buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multi-particulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including on or more layers and one or more concentric cylinders.

Abstract: Compositions, devices, method of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides and electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least on buffer elementt, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multi-particulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including on or more layers and one or more concentric cylinders.

Abstract: Compositions, devices, methods of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides an electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least one buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multiparticulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including one or more layers and one or more concentric cylinders.

Abstract: Compositions, devices, methods of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides an electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least one buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multiparticulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including one or more layers and one or more concentric cylinders.

Abstract: Disclosed herein are formulations of siRNA suitable for delivery by ocular iontophoresis, devices for iontophoretic delivery of siRNA and methods of use thereof.

Abstract: A new and distinct cultivar of boxwood that originated as a branch sport. The orderly arrangement of leaves on each stem gives this shrub considerable textural interest. This shrub displays excellent hardiness, and its emerald-green leaves retain their color through the winter. This semi-dwarf evergreen shrub displays an upright, dense growth habit, making it suitable for use in small gardens or as a low, formal hedge or border.

Abstract: A method of operating a computer to automatically produce production control software for a natural gas engine controller or a diesel engine controller is provided. The method includes the steps of (1) as a function of user input, defining a set specifications of the controller; and (2) producing control software to operate the controller as defined by the specifications.

Abstract: Articulated track supported land vehicles having both structure to effect major steering changes and minor steering changes wherein the minor changes are enabled by track warping mechanisms that utilize linear motors to selectively orient the direction of travel of track supporting wheels.

Abstract: A method of operating a computer to automatically produce production control software for a natural gas engine controller (104) on a machine is provided. The controller (104) is adapted to control a natural gas engine (106). The method includes the steps of (1) as a function of user input, defining a set of controller (104); and (2) producing control software to operate the controller (104) as defined by the specifications.